Eleusis was founded in 2013 as the world’s first company dedicated to the transformation of psychedelics into medicines. The company was co-founded by Shlomi Raz, and Charles Nichols, a current professor of pharmacology and experimental therapeutics at Louisiana State University.
As per a recent press release, “Eleusis has the unprecedented opportunity to address a broad spectrum of urgent, unmet needs through unlocking both the anti-inflammatory potential of psychedelics and their safe-use within psychiatry,” said Shlomi Raz, CEO and Chairman, Eleusis. The company’s collective IP portfolio, scientific and clinical research expertise, and advanced commercial development, are unrivaled, and enable Eleusis to pursue two significant opportunities:
Eleusis Therapeutics – realizing the anti-inflammatory potential of psychedelics
Eleusis Health Solutions – enabling broad access to safe and effective psychoactive drug therapy
Read more about Eleusis
Shlomi Raz | Chairman and Founder@Eleusis
Shlomi is the chairman and founder of Eleusis. Since founding Eleusis in 2013, Shlomi has overseen the company’s corporate and clinical development effort. Prior to founding Eleusis, Shlomi was a Managing Director at Goldman Sachs, and began his corporate career at JPMorgan.
Shlomi holds an MA from New York University and a BS from Georgetown University